deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT05740007

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

A Phase 2 Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW-3300 Administered Rectally for 12 Weeks to Treat Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Sponsor: Ironwood Pharmaceuticals, Inc.

Updated 21 times since 2023 Last updated: Feb 26, 2025 Started: Mar 28, 2023 Primary completion: Jan 23, 2025 Completion: Feb 6, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision

Listed as NCT05740007, this PHASE2 trial focuses on Bladder Pain Syndrome and Interstitial Cystitis and remains terminated or withdrawn. Sponsored by Ironwood Pharmaceuticals, Inc., it has been updated 21 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Mar 2025 — Sep 2025 [monthly]

    Terminated PHASE2

    Status: Active Not RecruitingTerminated

  3. Dec 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  4. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

Show 16 earlier versions
  1. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  2. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  3. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  4. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE2

  5. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  6. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  7. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  8. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  9. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  10. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  11. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  12. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  13. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  14. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  15. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  16. Mar 2023 — Apr 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ironwood Pharmaceuticals, Inc.
Data source: Ironwood Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .